Next-Generation Antibody Therapeutics Market to Grow Significantly due to Technological Advancements - Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Biogen Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Xencor Inc., Seattle Genetics Inc.

The prevalence of chronic diseases is rising rapidly, which is attributed to factors such as poor diet, unhealthy lifestyle, and excessive consumption of alcohol and tobacco. Cancer is among the leading causes of mortality around the world. As per the World Health Organization (WHO), in 2012, about 14 million new cases were registered, and 8.2 million people died due to cancer across the globe. In addition to this, according to the WHO, 63% of the deaths globally were caused by non-communicable diseases in 2008. Since, next-generation antibody therapeutics offer better treatment options for chronic diseases with minimum side effects, their demand is growing.

Request for sample copy of this report@ https://www.psmarketresearch.com/market-analysis/next-generation-antibody-market/report-sample

Antibody therapeutics which have improved efficacy, enhanced delivery, and are safer are referred to as next-generation antibody therapeutics. The next-generation antibody therapeutics market is projected to witness considerable growth in the coming years. Autoimmune/inflammatory and oncology are the two major therapeutic areas for which next-generation antibody therapeutics are utilized. Between these two, the larger demand for next-generation antibody therapeutics was created for oncology in the past. This is attributed to the fact that this treatment option provides benefits throughout the treatment of several cancer types, namely lung cancer, brain cancer, prostate cancer, colorectal cancer, and breast cancer.

Out of all the regions, namely Asia-Pacific, North America, Europe, and Rest of the World, North America accounted for the major share of the next-generation antibody therapeutics market in the past and is further projected to contribute the largest revenue share to the market in the coming years as well. The reason for this is the increasing research & development (R&D) activities and technological advancements in antibody therapeutics in the region. Apart from this, the surging prevalence of chronic diseases and growing healthcare expenditure are also resulting in the rising demand for next-generation antibody therapeutics in the region.

Get Detailed COVID-19 Impact Analysis on the Firefighting Foam Next-generation Antibody Therapeutics Market: https://www.psmarketresearch.com/speak-analyst/next-generation-antibody-market/Y292aWRfcXVlcnk=

This study covers

• Historical and the present size of the next-generation antibody therapeutics market
• Major factors driving the market and their impact during the short, medium, and long terms
• Market restraints and their impact during the short, medium, and long terms
• Recent trends and evolving opportunities for the market participants
• Historical and the present size of the market segments and understand their comparative future potential
• Potential of on-demand logistics services, so the market players make informed decisions on the sales of their offerings
• Competitive scenario of various next-generation antibody therapeutics market segments across key countries in several regions for uncovering market opportunities for the stakeholders

Contact:
P&S Intelligence
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Blog: http://psintelligence.blogspot.com/

About P&S Intelligence

P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

This release was published on openPR.